Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Husseini Manji

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Neurobiology of Aging|October 9, 2007
Protein kinase C activity is associated with prefrontal cortical decline in agingAvis R Brennan, Peixiong Yuan, Dara L Dickstein, et al.
Journal of Psychopharmacology (Oxford, England)|August 9, 2013
Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depressionAllison C Nugent, Paul J Carlson, Earle E Bain, et al.
The Journal of Clinical Psychiatry|May 16, 2020
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)Dong-Jing Fu, Dawn F Ionescu, Xiang Li, et al.
The International Journal of Neuropsychopharmacology|August 30, 2020
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)Dawn F Ionescu, Dong-Jing Fu, Xin Qiu, et al.
The American Journal of Psychiatry|April 17, 2018
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled StudyCarla M Canuso, Jaskaran B Singh, Maggie Fedgchin, et al.
Focus (American Psychiatric Publishing)|February 5, 2020
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled StudyCarla M Canuso, Jaskaran B Singh, Maggie Fedgchin, et al.
Biodata Mining|October 4, 2014
The genetic interacting landscape of 63 candidate genes in Major Depressive Disorder: an explorative studyMagnus Lekman, Ola Hössjer, Peter Andrews, et al.
The American Journal of Psychiatry|August 3, 2007
Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohortSilvia Paddock, Gonzalo Laje, Dennis Charney, et al.
Pharmacogenetics and Genomics|April 30, 2005
Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoreceptor gene polymorphism in healthy humansAlexander Neumeister, Dennis S Charney, Inna Belfer, et al.
JAMA Psychiatry|December 29, 2017
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical TrialElla J Daly, Jaskaran B Singh, Maggie Fedgchin, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Neurobiology of Aging|October 9, 2007
Protein kinase C activity is associated with prefrontal cortical decline in agingAvis R Brennan, Peixiong Yuan, Dara L Dickstein, et al.
Journal of Psychopharmacology (Oxford, England)|August 9, 2013
Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depressionAllison C Nugent, Paul J Carlson, Earle E Bain, et al.
The Journal of Clinical Psychiatry|May 16, 2020
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)Dong-Jing Fu, Dawn F Ionescu, Xiang Li, et al.
The International Journal of Neuropsychopharmacology|August 30, 2020
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)Dawn F Ionescu, Dong-Jing Fu, Xin Qiu, et al.
The American Journal of Psychiatry|April 17, 2018
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled StudyCarla M Canuso, Jaskaran B Singh, Maggie Fedgchin, et al.
Focus (American Psychiatric Publishing)|February 5, 2020
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled StudyCarla M Canuso, Jaskaran B Singh, Maggie Fedgchin, et al.
Biodata Mining|October 4, 2014
The genetic interacting landscape of 63 candidate genes in Major Depressive Disorder: an explorative studyMagnus Lekman, Ola Hössjer, Peter Andrews, et al.
The American Journal of Psychiatry|August 3, 2007
Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohortSilvia Paddock, Gonzalo Laje, Dennis Charney, et al.
Pharmacogenetics and Genomics|April 30, 2005
Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoreceptor gene polymorphism in healthy humansAlexander Neumeister, Dennis S Charney, Inna Belfer, et al.
JAMA Psychiatry|December 29, 2017
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical TrialElla J Daly, Jaskaran B Singh, Maggie Fedgchin, et al.
Pageof 4